Presentamos el caso de una paciente de 44 años estudiada por amenorrea e hiperprolactinemia. No refería galactorrea, cefalea ni alteraciones en la visión. HIPERPROLACTINEMIA Y PROLACTINOMA. MP Diagnóstico específico: PRL se deben medir en todo paciente con hipogonadismo o. A hiperprolactinemia causa hipogonadismo hipogonadotrófico principalmente por inibir a secreção pulsátil do GnRH, além de inibir diretamente a.

Author: Samusar Brajin
Country: Spain
Language: English (Spanish)
Genre: Science
Published (Last): 7 June 2015
Pages: 335
PDF File Size: 8.50 Mb
ePub File Size: 11.79 Mb
ISBN: 476-8-31621-438-1
Downloads: 64396
Price: Free* [*Free Regsitration Required]
Uploader: Tauramar

Quality of life in women with microprolactinoma treated with dopamine agonists. Diagnosis and treatment of yperprolactinemia: Orphanet J Rare Dis. A PRL pode ser classificada nas seguintes isoformas, de hiperprolactinnemia com o peso molecular: Nos macroprolactinomas, o manejo deve ser individualizado.

J Clin Endocrinol Metab.


Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline.

Vertebral fractures in males with prolactinoma. Prolactinomas are the most common pituitary adenomas that affect young women at fertile age.

[Current diagnosis and treatment of hyperprolactinemia].

N Engl J Med. Spontaneous and medically induced cerebrospinal fluidleakage in the setting of pituitary adenomas: Restoration of ovarian cyclicity and ovulation induction in hypopituitary women.


Searching in Epistemonikos database, which is maintained by screening 30 databases, we identified two systematic reviews including 12 studies addressing the question of this article, including five randomized controlled trials. Endocrine aspects of male sexual dysfunctions.

Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: A study of patients with histologically verified non-functioning pituitary macroadenoma. Kluwer Academic Publishers; Recurrence of hyperprolactinemia after withdrawal amenogrea dopamine agonists: Para un estudio no se especifican dosis de cabergolina y bromocriptina en ninguna de las revisiones identificadas [11].

How to cite this article.

There was a problem providing the content you requested

Mah PM, Webster J. Results of a national multicenter randomized double-blind study]. Prolactinomas resistant to standard doses of cabergoline: Serum prolactin concentration at presentation of non-functioning pituitary macroadenomas.

Twenty-four hour secretory patterns of prolactin in women.

Cancer risk in hyperprolactinemia patients: Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: Once physiological causes such as pregnancy, systemic disorders such as primary hypothyroidism and the use of drugs with dopamine antagonistic actions such as metochlopramide have been ruled out, the most common cause of hyperprolactinemia is a PRL-secreting pituitary adenoma or amenofrea.


A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas.

Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment.

Cabergoline and bromocriptine are among the most commonly used drugs to treat prolactinoma. Diagnosis and treatment of hyperprolactinemia: Dopamine as a prolactin PRL inhibitor.

[Current diagnosis and treatment of hyperprolactinemia].

A paciente deve ser monitorada clinicamente a cada trimestre. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males.

Su principal desarrollo es la base de datos Epistemonikos www. Pituitary tumors in pregnancy. The risk for breast cancer is not evidently hipperprolactinemia in women with hyperprolactinemia.

We combined the evidence using meta-analysis and generated a summary of findings following the GRADE approach. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas.